Project description
Biomechanical biomarkers for predicting immunotherapy response
Cancer immunotherapy causes severe toxicities in some cases, underscoring the importance of biomarkers that can predict non-responders in a timely manner. To address this issue, the EU-funded Immuno-Predictor project is working under the hypothesis that certain biomechanical aspects of the tumour microenvironment, such as tumour stiffness, solid stress, perfusion and hypoxia, are responsible for the resistance to immunotherapy. Systemic administration of immunotherapy requires a well-perfused vascular system, and that is often not the case in stiff and hypoxic tumours. Using clinically applied, ultrasound-based methods and computational biomechanical modelling in tumour-bearing mice and cancer patients, Immuno-Predictor scientists will identify biomechanical biomarkers to predict immunotherapy outcome.
Objective
Immunotherapy has revolutionized the treatment of multiple cancers and has already become a standard of care for some tumor types. However, a majority of patients do not benefit from current immunotherapeutics and many develop severe toxicities. Therefore, the identification of biomarkers to classify patients as likely responders or nonresponders to immunotherapy is a timely and of tremendous impact task. My hypothesis is that biomechanical aspects of the tumor microenvironment mediate resistance to immunotherapy. Specifically, many tumors stiffen as they grow and also, tumor growth within the host tissue generates mechanical forces, termed solid stress. Tumor stiffening and solid stress are distinct mechanical abnormalities that compress intratumoral blood vessels, causing hypo-perfusion and hypoxia. Systemic administration of immunotherapeutics requires a well-perfused vasculature, whereas hypo-perfusion and hypoxia promote immunosuppression, helping cancer cells to evade immune responses. The objective of the proposed research is the identification of novel Mechanical Biomarkers related to tumor stiffness, solid stress, perfusion and hypoxia for prediction of immunotherapy. Tumor-bearing mice will be developed and treated with immunotherapeutic drugs and clinically used methods will be combined with computational biomechanical modeling for measuring the Mechanical Biomarkers, making the research transferable to the clinic. The biomarkers will be benchmarked against tumor normalization strategies aiming to restore/normalize mechanical abnormalities and optimize immunotherapy. Finally, the clinical utility of the selected biomarkers will be evaluated in human tumors. Only few tumor-specific biomarkers are used in the clinic - based mainly on genomic analysis. This project is expected to lead to the first biomarkers for immunotherapy prediction exploiting tumor mechanics.
Fields of science
Programme(s)
Funding Scheme
ERC-COG - Consolidator GrantHost institution
1678 Nicosia
Cyprus